ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

has the potential to provide extended and continuous red blood cell transfusion independence; (v) that Geron is preparing to commercialize RYTELO in select EU countries in 2026, pending country-by ...

Geron (GERN) Corporation announced that the European ... where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and ...

Geron Co. (NASDAQ:GERN – Get Free Report) hit a new 52-week low during trading on Wednesday .The stock traded as low as $1.45 and last traded at $1.48, with a volume of 31179782 shares trading hands ...

Geron Corp's imetelstat ... Imetelstat is approved for patients with lower risk MDS who have anemia (low red blood cells) and who cannot receive certain drugs designed to stimulate blood cell ...